Screener
Alto Neuroscience ANRO EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Alto Neuroscience in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Alto Neuroscience’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 7:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001999480-26-000012
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Net loss | $(26,237) | $(15,169) |
| Other comprehensive income (loss): | ||
| Change in fair value attributable to instrument specific credit risk | 7 | 134 |
| Foreign currency translation | (16) | (19) |
| Total other comprehensive income (loss) | (9) | 115 |
| Comprehensive loss | $(26,246) | $(15,054) |
| Net loss per share attributable to common stockholders, basic and diluted | $(0.80) | $(0.56) |
| Weighted-average number of common shares outstanding, basic and diluted | 32,893 | 27,049 |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Alto Neuroscience's EPS (diluted)?
- Alto Neuroscience (ANRO) reported EPS (diluted) of -$0.80 in Q1 2026.
- How has Alto Neuroscience's EPS (diluted) changed year-over-year?
- Alto Neuroscience's EPS (diluted) decreased by 42.9% year-over-year, from -$0.56 to -$0.80.
- What is the long-term trend for Alto Neuroscience's EPS (diluted)?
- Over 2 years (2023 to 2025), Alto Neuroscience's EPS (diluted) has grown at a -52.6% compound annual growth rate (CAGR), from -$9.72 to -$2.18.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Alto Neuroscience's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude